331 related articles for article (PubMed ID: 34899721)
1. Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review.
Ye Y; Xu C; Chen F; Liu Q; Cheng N
Front Immunol; 2021; 12():771201. PubMed ID: 34899721
[TBL] [Abstract][Full Text] [Related]
2. Type I interferon-mediated tumor immunity and its role in immunotherapy.
Yu R; Zhu B; Chen D
Cell Mol Life Sci; 2022 Mar; 79(3):191. PubMed ID: 35292881
[TBL] [Abstract][Full Text] [Related]
3. Innate immune cells in the tumor microenvironment.
Li MO; Wolf N; Raulet DH; Akkari L; Pittet MJ; Rodriguez PC; Kaplan RN; Munitz A; Zhang Z; Cheng S; Bhardwaj N
Cancer Cell; 2021 Jun; 39(6):725-729. PubMed ID: 34129817
[TBL] [Abstract][Full Text] [Related]
4. Histamine in cancer immunology and immunotherapy. Current status and new perspectives.
Sarasola MP; Táquez Delgado MA; Nicoud MB; Medina VA
Pharmacol Res Perspect; 2021 Oct; 9(5):e00778. PubMed ID: 34609067
[TBL] [Abstract][Full Text] [Related]
5. Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling.
Brown MC; Mosaheb MM; Mohme M; McKay ZP; Holl EK; Kastan JP; Yang Y; Beasley GM; Hwang ES; Ashley DM; Bigner DD; Nair SK; Gromeier M
Nat Commun; 2021 Mar; 12(1):1858. PubMed ID: 33767151
[TBL] [Abstract][Full Text] [Related]
6. Innate myeloid cells in the tumor microenvironment.
Duhan V; Smyth MJ
Curr Opin Immunol; 2021 Apr; 69():18-28. PubMed ID: 33588308
[TBL] [Abstract][Full Text] [Related]
7. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.
Burugu S; Asleh-Aburaya K; Nielsen TO
Breast Cancer; 2017 Jan; 24(1):3-15. PubMed ID: 27138387
[TBL] [Abstract][Full Text] [Related]
8. Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression.
Bruno A; Mortara L; Baci D; Noonan DM; Albini A
Front Immunol; 2019; 10():771. PubMed ID: 31057536
[TBL] [Abstract][Full Text] [Related]
9. The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.
Law AM; Lim E; Ormandy CJ; Gallego-Ortega D
Endocr Relat Cancer; 2017 Apr; 24(4):R123-R144. PubMed ID: 28193698
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-33 in Malignancies: Friends or Foes?
Shen JX; Liu J; Zhang GJ
Front Immunol; 2018; 9():3051. PubMed ID: 30619376
[TBL] [Abstract][Full Text] [Related]
11. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
12. A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.
Ma HS; Poudel B; Torres ER; Sidhom JW; Robinson TM; Christmas B; Scott B; Cruz K; Woolman S; Wall VZ; Armstrong T; Jaffee EM
Cancer Immunol Res; 2019 Mar; 7(3):428-442. PubMed ID: 30642833
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model.
Nascimento C; Ferreira F
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188587. PubMed ID: 34237352
[TBL] [Abstract][Full Text] [Related]
14. The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies.
Baxevanis CN; Fortis SP; Perez SA
Semin Cancer Biol; 2021 Jul; 72():76-89. PubMed ID: 31881337
[TBL] [Abstract][Full Text] [Related]
15. Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.
Corrales L; Gajewski TF
Cytokine; 2016 Jan; 77():245-7. PubMed ID: 26315534
[No Abstract] [Full Text] [Related]
16. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
[TBL] [Abstract][Full Text] [Related]
17. Innate lymphoid cells and cancer: Role in tumor progression and inhibition.
Yuan X; Rasul F; Nashan B; Sun C
Eur J Immunol; 2021 Sep; 51(9):2188-2205. PubMed ID: 34189723
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity.
Chen L; He Z; Qin L; Li Q; Shi X; Zhao S; Chen L; Zhong N; Chen X
PLoS One; 2011; 6(9):e24407. PubMed ID: 21931708
[TBL] [Abstract][Full Text] [Related]
19. Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I Interferons to Activate Antigen-Presenting Cells and Induce Antigen-Specific Antitumor Immunity.
Levy ES; Chang R; Zamecnik CR; Dhariwala MO; Fong L; Desai TA
Mol Pharm; 2021 Mar; 18(3):1014-1025. PubMed ID: 33541072
[TBL] [Abstract][Full Text] [Related]
20. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response.
Liang X; Li L; Li X; He T; Gong S; Zhu S; Zhang M; Wu Q; Gong C
Theranostics; 2021; 11(14):6936-6949. PubMed ID: 34093863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
